Imbria Pharmaceuticals
PrivateLast Round
Series B
Nov 17, 2025
Est. Valuation
$189.2M
Total Funding Raised
$281.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Imbria Pharmaceuticals operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in November 2025.
Imbria Pharmaceuticals is a biotechnology company that develops innovative therapies aimed at restoring cellular energy production in patients with cardiometabolic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Imbria Pharmaceuticals Comparables
Compare Imbria Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cardurion Pharmaceuticals | 84% | |
| Thryv Therapeutics | 83% | |
| Zhejiang Jixing Auto Parts Co., Ltd. | 76% |
For institutional investors. Book with your work email.
Imbria Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 17, 2025 | ||||
| Series B | Apr 10, 2025 | ||||
| Series A | Jul 2, 2020 | ||||
| Seed | Jul 9, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Imbria Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B, Seed, Series A |
| SV Health Investors | Series B, Seed, Series A |
| AXA IM Alts | Series B |
| Deep Track Capital | Series B |
| Catalio Capital Management | Series B |
| AN Venture Partners | Series B |
| BNP Paribas Asset Management | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 46% MoM.
- Nov 17, 2025
Zina Affas Besse joins the Board of Directors.
For institutional investors. Book with your work email.
Imbria Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Imbria Pharmaceuticals's valuation, stock price, and market status.
Is Imbria Pharmaceuticals a public or private company?
Imbria Pharmaceuticals is a private company.
What is the current stock price of Imbria Pharmaceuticals?
Imbria Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Imbria Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Imbria Pharmaceuticals worth (valuation)?
Imbria Pharmaceuticals's valuation is estimated at $189.2M based on funding round data.
Can I buy Imbria Pharmaceuticals stock?
Imbria Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Imbria Pharmaceuticals's last funding round?
Imbria Pharmaceuticals's most recent funding round was Series B on November 17, 2025.
Who are the main investors in Imbria Pharmaceuticals?
Key investors in Imbria Pharmaceuticals include Deep Track Capital.
Will Imbria Pharmaceuticals IPO soon?
No public IPO plans have been announced for Imbria Pharmaceuticals.
How can I track Imbria Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Imbria Pharmaceuticals's shares on secondary markets.